PL356422A1 - Inhibitory TNF-a - Google Patents
Inhibitory TNF-aInfo
- Publication number
- PL356422A1 PL356422A1 PL01356422A PL35642201A PL356422A1 PL 356422 A1 PL356422 A1 PL 356422A1 PL 01356422 A PL01356422 A PL 01356422A PL 35642201 A PL35642201 A PL 35642201A PL 356422 A1 PL356422 A1 PL 356422A1
- Authority
- PL
- Poland
- Prior art keywords
- tnf
- alpha inhibitors
- inhibitors
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000046828 | 2000-02-18 | ||
PCT/JP2001/001069 WO2001060362A1 (en) | 2000-02-18 | 2001-02-15 | TNF-α INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
PL356422A1 true PL356422A1 (pl) | 2004-06-28 |
Family
ID=18569174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL01356422A PL356422A1 (pl) | 2000-02-18 | 2001-02-15 | Inhibitory TNF-a |
Country Status (10)
Country | Link |
---|---|
US (1) | US6833381B2 (pl) |
EP (1) | EP1262180A4 (pl) |
KR (1) | KR20030016229A (pl) |
CN (1) | CN1404390A (pl) |
AU (2) | AU2001234088B2 (pl) |
CA (1) | CA2400124C (pl) |
HU (1) | HUP0301057A3 (pl) |
NO (1) | NO20023913L (pl) |
PL (1) | PL356422A1 (pl) |
WO (1) | WO2001060362A1 (pl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100224601B1 (ko) * | 1997-05-13 | 1999-10-15 | 윤종용 | 복합기의 자동 급지장치 |
WO2002034263A1 (fr) * | 2000-10-25 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Agents preventifs/remedes destines a l'hypertension portale |
US20040097565A1 (en) * | 2001-01-29 | 2004-05-20 | Terashita Zen-Ichi | Analgesic and antiinflammatory drugs |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
DE50201240D1 (de) * | 2001-04-23 | 2004-11-11 | Amaxa Gmbh | Pufferlössung für die elektroporation und verfahren umfassend die verwendung derselben |
WO2003041739A1 (en) * | 2001-11-13 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Anticaner agents |
JP4484427B2 (ja) * | 2001-12-03 | 2010-06-16 | 武田薬品工業株式会社 | インスリン抵抗性改善剤 |
EP1452176A4 (en) * | 2001-12-03 | 2009-01-21 | Takeda Pharmaceutical | MEANS FOR IMPROVING INSULIN RESISTANCE |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
EP1579872B8 (en) * | 2002-12-27 | 2012-11-07 | Takeda Pharmaceutical Company Limited | Body weight gain inhibitor |
US20050201989A1 (en) * | 2004-02-19 | 2005-09-15 | St. Camillus Medical, Inc. | Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha |
CA2563810A1 (en) * | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
US20070054948A1 (en) * | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
KR100953878B1 (ko) * | 2004-09-02 | 2010-04-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 올메살탄 메독소밀의 정제 |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
SI1891952T1 (sl) * | 2006-05-04 | 2012-02-29 | Lek Pharmaceuticals, D.D. | Farmacevtski sestavek, ki vsebuje olmesartan medoksomil |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
MX2009010167A (es) * | 2007-03-28 | 2009-10-12 | Takeda Pharmaceutical | Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph. |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
EP2321281A4 (en) | 2008-09-02 | 2011-09-28 | Elder Pharmaceuticals Ltd | INFLAMMATORY CONNECTIONS |
EP2858983B1 (en) * | 2012-06-11 | 2018-04-18 | UCB Biopharma SPRL | Tnf-alpha modulating benzimidazoles |
GB201321733D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321746D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015126944A1 (en) | 2014-02-18 | 2015-08-27 | Henkin Robert I | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
GB201620948D0 (en) * | 2016-12-09 | 2017-01-25 | Ucb Biopharma Sprl | Therapeutic agents |
CA3060316A1 (en) * | 2017-04-28 | 2018-11-01 | Asana Biosciences, Llc | Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
CA2115985A1 (en) * | 1993-02-25 | 1994-08-26 | Kohei Nishikawa | Vascular hypertrophy suppressor |
JP2787539B2 (ja) * | 1993-02-26 | 1998-08-20 | 松森 昭 | ウイルス性疾患の予防または治療剤 |
JP3810020B2 (ja) * | 1993-04-22 | 2006-08-16 | 武田薬品工業株式会社 | 腎疾患の予防または治療剤 |
US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
MX9603259A (es) | 1994-02-08 | 1997-03-29 | Novartis Ag | Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii. |
SE9501881D0 (sv) * | 1995-05-19 | 1995-05-19 | Astra Ab | New pharmacological use of AII-receptor antagonists |
KR19990022723A (ko) * | 1995-06-07 | 1999-03-25 | 윌리암스 로저 에이 | 울혈성심부전의 치료를 위한 스피로노락톤 및 앤지오텐신 ii 길 항제 복합요법 |
CA2224451A1 (en) * | 1995-06-30 | 1997-01-23 | Merck & Co., Inc. | Method of treating renal disease using an ace inhibitor and an aii antagonist |
CZ297941B6 (cs) | 1996-04-05 | 2007-05-02 | Takeda Pharmaceutical Company Limited | Farmaceutický prípravek obsahující slouceninu s antagonickým úcinkem k angiotensinu II |
IL130599A0 (en) * | 1997-01-10 | 2000-06-01 | Merck & Co Inc | Use of angiotensin II antagonists to treat symptomatic heart failure |
US6300356B1 (en) * | 1998-02-25 | 2001-10-09 | Merck & Co., Inc. | Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist |
ID25640A (id) * | 1998-03-04 | 2000-10-19 | Takeda Chemical Industries Ltd | Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya |
JP2000159671A (ja) * | 1998-12-01 | 2000-06-13 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
-
2001
- 2001-02-15 US US10/203,805 patent/US6833381B2/en not_active Expired - Fee Related
- 2001-02-15 KR KR1020027010709A patent/KR20030016229A/ko not_active Application Discontinuation
- 2001-02-15 EP EP01906130A patent/EP1262180A4/en not_active Withdrawn
- 2001-02-15 WO PCT/JP2001/001069 patent/WO2001060362A1/ja active IP Right Grant
- 2001-02-15 AU AU2001234088A patent/AU2001234088B2/en not_active Ceased
- 2001-02-15 CA CA2400124A patent/CA2400124C/en not_active Expired - Fee Related
- 2001-02-15 CN CN01805019A patent/CN1404390A/zh active Pending
- 2001-02-15 PL PL01356422A patent/PL356422A1/pl not_active Application Discontinuation
- 2001-02-15 HU HU0301057A patent/HUP0301057A3/hu unknown
- 2001-02-15 AU AU3408801A patent/AU3408801A/xx not_active Withdrawn
-
2002
- 2002-08-16 NO NO20023913A patent/NO20023913L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1404390A (zh) | 2003-03-19 |
CA2400124A1 (en) | 2001-08-23 |
EP1262180A4 (en) | 2005-06-01 |
NO20023913D0 (no) | 2002-08-16 |
CA2400124C (en) | 2010-12-14 |
US6833381B2 (en) | 2004-12-21 |
HUP0301057A3 (en) | 2004-01-28 |
HUP0301057A2 (hu) | 2003-12-29 |
AU3408801A (en) | 2001-08-27 |
WO2001060362A1 (en) | 2001-08-23 |
NO20023913L (no) | 2002-09-10 |
EP1262180A1 (en) | 2002-12-04 |
KR20030016229A (ko) | 2003-02-26 |
AU2001234088B2 (en) | 2005-12-01 |
US20030055039A1 (en) | 2003-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3408801A (en) | Tnf-alpha inhibitors | |
AU2001234088A1 (en) | TNF-alpha inhibitors | |
AU8212901A (en) | Deacetylase inhibitors | |
HK1081545A1 (en) | Vla-4 inhibitors | |
GB9900416D0 (en) | Inhibitors | |
IL150964A0 (en) | Protease inhibitors | |
EP1324759A4 (en) | NF - G (K) B INHIBITORS | |
IL156479A0 (en) | Substituted-8-arylquinoline phosphodiesterase-4 inhibitors | |
DE60142731D1 (en) | Ation | |
EP1277730A4 (en) | HEMMER OF NEOVASCULARIZATION | |
IL153421A0 (en) | Protease inhibitors | |
AU2001232245A1 (en) | Tnf- alpha inhibitors | |
HUP0600331A2 (en) | Farnesyltransferase inhibitors | |
EP1153022A4 (en) | PROTEASE INHIBITORS | |
GB0030284D0 (en) | Enzyme inhibitors | |
IL151087A0 (en) | Protease inhibitors | |
HUP0301964A2 (en) | Protease inhibitors | |
GB0015996D0 (en) | Inhibitors | |
GB0021193D0 (en) | Inhibitors | |
GB0029733D0 (en) | Inhibitors | |
GB0029730D0 (en) | Inhibitors | |
GB0004895D0 (en) | Inhibitor | |
GB0005017D0 (en) | Inhibitor | |
ZA200003398B (en) | Inhibitors. | |
ZA200003399B (en) | Inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |